Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 4/2019

21-11-2018

Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1

Auteurs: James W. Varni, Kavitha Nutakki, Nancy L. Swigonski

Gepubliceerd in: Quality of Life Research | Uitgave 4/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Objectives

The aim was to investigate pain, skin sensations symptoms and patient self-reported, and parent proxy-reported cognitive functioning as predictors of generic health-related quality of life (HRQOL) in pediatric patients with Neurofibromatosis Type 1 (NF1) from the perspectives of patients and parents.

Methods

The Pain, Skin Itch Bother, Skin Sensations, and Cognitive Functioning Scales from the PedsQL™ Neurofibromatosis Type 1 Module and the PedsQL™ Generic Core Scales were completed in a multi-site national study by 323 patients and 335 parents. Patients were 5–25 years of age. Pain and skin symptoms and cognitive functioning were tested for bivariate and multivariate linear associations with generic HRQOL.

Results

Pain, skin itch bother, skin sensations, and cognitive functioning were associated with decreased HRQOL in bivariate analyses (Ps < 0.001). In predictive analytics models, utilizing hierarchical multiple regression analyses controlling for demographic covariates, pain, skin itch bother, skin sensations, and cognitive functioning as a group accounted for 61 percent of the variance in patient-reported generic HRQOL (P < 0.001), reflecting a large effect size. For parent proxy-report, the predictor variables as a group accounted for 53% of the variance in generic HRQOL.

Conclusions

Pain, skin symptoms, and patient self-reported and parent proxy-reported cognitive functioning are key predictors of generic HRQOL in pediatric patients with NF1. Delineating NF1-specific symptoms and cognitive functioning as high-priority predictors from the patient and parents perspective enhances a family-centered approach in clinical research, clinical trials, and clinical practice intended to improve the global generic HRQOL of pediatric patients with NF1.
vorige artikel Health-related quality of life assessment among people living with HIV in Rio de Janeiro, Brazil: a cross-sectional study
volgende artikel Association between medication adherence and quality of life of patients with diabetes and hypertension attending primary care clinics: a cross-sectional survey
Literatuur
1.
Monroe, C. L., Dahiya, S., & Gutmann, D. H. (2017). Dissecting clinical heterogeneity in Neurofibromatosis Type 1. Annual Review of Pathology, 12, 53–74.CrossRefPubMed
2.
Blakeley, J. O., & Plotkin, S. R. (2016). Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology, 18, 624–638.CrossRefPubMedCentralPubMed
3.
Vranceanu, A. M., Merker, V. L., Park, E. R., & Plotkin, S. R. (2015). Quality of life among children and adolescents with Neurofibromatosis 1: A systematic review of the literature. Journal of Neuro-Oncology, 122, 219–228.CrossRefPubMed
4.
Nutakki, K., Hingtgen, C. M., Monahan, P., Varni, J. W., & Swigonski, N. L. (2013). Development of the adult PedsQL Neurofibromatosis Type 1 Module: Initial feasibility, reliability and validity. Health and Quality of Life Outcomes, 11, 21.CrossRefPubMedCentralPubMed
5.
Nutakki, K., Varni, J. W., Steinbrenner, S., Draucker, C. B., & Swigonski, N. L. (2017). Development of the Pediatric Quality of Life Inventory Neurofibromatosis Type 1 Module items for children, adolescents and young adults: Qualitative methods. Journal of Neuro-Oncology, 132, 135–143.CrossRefPubMed
6.
Draucker, C. B., Nutakki, K., Varni, J. W., & Swigonski, N. L. (2017). The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis of narratives. Journal for Specialists in Pediatric Nursing, 22, e12174.CrossRef
7.
Nutakki, K., Varni, J. W., & Swigonski, N. L. (2018). PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: Feasibility, reliability, and validity. Journal of Neuro-Oncology, 137, 337–347.CrossRefPubMed
8.
Varni, J. W., Seid, M., & Kurtin, P. S. (2001). PedsQL™ 4.0: Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Medical Care, 39, 800–812.CrossRefPubMed
9.
Varni, J. W., & Limbers, C. A. (2009). The PedsQL™ 4.0 Generic Core Scales young adult version: Feasibility, reliability and validity in a university student population. Journal of Health Psychology, 14, 611–622.CrossRefPubMed
10.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Erlbaum.
11.
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.). Mahwah: Erlbaum.
12.
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16, 297–334.CrossRef
13.
Créange, A., Zeller, J., Rostaing-Rigattieri, S., Brugières, P., Degos, J. D., Revuz, J., & Wolkenstein, P. (1999). Neurological complications of neurofibromatosis type 1 in adulthood. Brain, 122, 473–481.CrossRefPubMed
14.
DiMario, F. J., & Langshur, S. (2000). Headaches in patients with neurofibromatosis-1. Journal of Child Neurology, 15, 235–238.CrossRefPubMed
15.
Bardo-Brouard, P., Luizard, C., Valeyrie-Allanore, L., Goujon, C., Do, B., Colin, A., Wolkenstein, P., & Paul, M. (2018). High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: A case series. Current Medical Research and Opinion, 34, 887–891.CrossRefPubMed
16.
Brenaut, E., Nizery-Guermeur, C., Audebert-Bellanger, S., Ferkal, S., Wolkenstein, P., Misery, L., & Abasq-Thomas, C. (2016). Clinical characteristics of pruritus in neurofibromatosis 1. Acta Dermato-Venereologica, 96, 398–399.CrossRefPubMed
17.
Khosrotehrani, K., Bastuji-Garin, S., Riccardi, V. M., Birch, P., Friedman, J. M., & Wolkenstein, P. (2005). Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients. American Journal of Medical Genetics Part A, 132A, 49–53.CrossRefPubMed
18.
Ozonoff, S. (1999). Cognitive impairment in neurofibromatosis type 1. American Journal of Medical Genetics, 89, 45–52.CrossRefPubMed
19.
Hyman, S. L., Shores, A., & North, K. N. (2005). The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology, 65, 1037–1044.CrossRefPubMed
20.
Schwetye, K. E., & Gutmann, D. H. (2014). Cognitive and behavioral problems in children with neurofibromatosis type 1: Challenges and future directions. Expert Review of Neurotherapeutics, 14, 1139–1152.CrossRefPubMed
21.
Payne, J. M., Hyman, S. L., Shores, E. A., & North, K. N. (2011). Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychology, 17, 313–329.CrossRefPubMed
22.
Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). Impaired health-related quality of life in children and adolescents with chronic conditions: A comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic Core Scales. Health and Quality of Life Outcomes, 5(43), 1–15.CrossRefPubMedCentralPubMed
23.
Nguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V. F. (2011). Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits. Journal of Pediatrics, 159, 652–655.CrossRefPubMed
24.
Varni, J. W., Limbers, C. A., & Newman, D. A. (2009). Using factor analysis to confirm the validity of children’s self-reported health-related quality of life across different modes of administration. Clinical Trials, 6, 185–195.CrossRefPubMed
25.
Ater, J. L., Xia, C., Booth, M. M. C., Freyer, T. N., Packer, D. R., Sposto, R. J., Vezina, R., G., & Pollack, I. F. (2016). Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children’s Oncology Group. Cancer, 122, 1928–1936.CrossRefPubMed
Metagegevens
Titel
Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1
Auteurs
James W. Varni
Kavitha Nutakki
Nancy L. Swigonski
Publicatiedatum
21-11-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-2055-5

Andere artikelen Uitgave 4/2019

Quality of Life Research 4/2019 Naar de uitgave

OriginalPaper

Health-related quality of life (HRQoL) in children of ill or substance abusing parents: examining factor structure and sub-group differences

OriginalPaper

Developmental coordination disorder: the impact on the family

OriginalPaper

Measurement invariance of the Satisfaction with Life Scale by gender, age, marital status and educational level

OriginalPaper

The weight-specific adolescent instrument for economic evaluation (WAItE): psychometric evaluation using a Rasch model approach

OriginalPaper

Health-related quality of life predicted subsequent health care resource utilization in patients with active cancer

OriginalPaper

Is it possible to determine the level of functional impairment that distinguishes the patients with ADHD from those without ADHD?